危重患者利尿治疗:系统评价与网络Meta分析
该系统评价与贝叶斯随机效应网络Meta分析纳入26项RCT、1652例危重成人,比较不同利尿策略用于液体清除。与袢利尿剂单次推注相比,持续输注对死亡率影响不确定(OR 1.26;95% CrI 0.62–2.55;极低确定性),可能增加ICU住院时间(MD 1.56天;95% CrI -0.02–3.16;低确定性)。托伐普坦单药治疗可能减少急性肾损伤(OR 0.12;95% CrI 0.01–0.87;低确定性),但其对后续肾脏替代治疗需求和死亡率的影响仍不确定。证据主要来自心力衰竭和心血管术后人群。
要点
- 与袢利尿剂单次推注相比,持续袢利尿剂输注对死亡率影响不确定(OR 1.26;95% CrI 0.62–2.55;极低确定性)。
- 持续袢利尿剂输注可能增加ICU住院时间(MD 1.56天;95% CrI -0.02–3.16;低确定性),但置信区间跨0。
- 与袢利尿剂单次推注或持续输注相比,托伐普坦单药治疗可能减少急性肾损伤(OR 0.12;95% CrI 0.01–0.87;低确定性)。
- 无研究评估托伐普坦对肾脏替代治疗需求的影响;其对死亡率的影响仍不确定。
- 多数其他比较和结局的证据确定性为低或极低,且证据主要来自心力衰竭和心血管术后人群。
适用人群与场景
- 危重成人,需在ICU级治疗中主动清除液体,且肾功能保留(原文:patients with preserved renal function)。
- 纳入的RCT证据主要来自心力衰竭和心血管术后人群;原文未明确其他纳入/排除标准。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值;仅评价了袢利尿剂单次推注、持续输注、口服袢利尿剂、托伐普坦单药及袢利尿剂联合托伐普坦、螺内酯、噻嗪类、乙酰唑胺或氨苯蝶啶等策略。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与贝叶斯随机效应网络Meta分析,纳入26项RCT、1652例危重成人。
- 与袢利尿剂单次推注相比,持续袢利尿剂输注对死亡率影响不确定(OR 1.26;95% CrI 0.62–2.55;极低确定性)。
- 与袢利尿剂单次推注相比,持续袢利尿剂输注可能增加ICU住院时间(MD 1.56天;95% CrI -0.02–3.16;低确定性)。
- 与袢利尿剂单次推注或持续输注相比,托伐普坦单药治疗可能减少急性肾损伤(OR 0.12;95% CrI 0.01–0.87;低确定性);无研究评估其对肾脏替代治疗需求的影响。
- 多数其他比较和结局的证据确定性为低或极低。
证据类型、等级与局限
- 证据类型:系统评价与网络Meta分析(RCT)。
- 证据分级:采用GRADE方法评价证据确定性;死亡率比较为极低确定性,ICU住院时间为低确定性,托伐普坦减少急性肾损伤为低确定性。
- 局限:证据临床异质性大,主要来自心力衰竭和心血管术后人群;多数比较和结局确定性低或极低;托伐普坦对肾脏替代治疗需求和死亡率的影响不确定。
对床旁实践的改变
- 对于危重成人液体清除,袢利尿剂单次推注在患者重要结局上至少与其他利尿策略相当,可考虑作为默认策略之一,但证据确定性低或极低。
- 持续袢利尿剂输注可能增加ICU住院时间,选择时需权衡,尤其在不明确获益的情况下。
- 托伐普坦单药可能减少急性肾损伤,但对其肾脏替代治疗需求和死亡率的影响不确定,不能据此常规推荐;适用人群应限于证据所涵盖的心力衰竭和心血管术后等,原文未提及其他人群。
指南或共识出处
- 原文未提及具体指南或共识名称;系统评价与网络Meta分析发表于Annals of Intensive Care。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fluid overload is common in critically ill patients and is associated with worse outcomes. Diuretics are the mainstay of active fluid removal in patients with preserved renal function. The optimal diuretic strategy for fluid removal remains uncertain.
METHODS: We conducted a systematic review and Bayesian random-effects network meta-analysis of randomized controlled trials comparing two or more diuretic strategies for fluid removal in critically ill adults. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials via Ovid, as well as trial registries, from inception to November 20, 2025. Two reviewers independently extracted data and assessed risk of bias using ROBUST-RCT. Certainty of evidence was evaluated using the GRADE approach for network meta-analysis. Treatment effects were summarized as odds ratios (ORs) or mean differences (MDs) with 95% credible intervals (CrIs).
RESULTS: Twenty-six randomized controlled trials involving 1,652 participants were included. Evaluated interventions included bolus loop diuretics (19 studies), continuous loop infusion (15 studies), oral loop diuretics (5 studies), and loop diuretics combined with tolvaptan (8 studies), spironolactone (3 studies), thiazides (2 studies), acetazolamide (1 study), or triamterene (1 study). Compared with bolus loop diuretics, continuous loop infusion had an uncertain effect on mortality (OR 1.26; 95% CrI 0.62 to 2.55; very low certainty) and may increase ICU length of stay (MD 1.56 days; 95% CrI -0.02 to 3.16; low certainty). Tolvaptan monotherapy may reduce acute kidney injury compared with bolus or continuous loop diuretics (OR 0.12; 95% CrI 0.01 to 0.87; low certainty), although no studies evaluated its effect on the need for renal replacement therapy. For most other comparisons and outcomes, the certainty of evidence was low or very low.
CONCLUSIONS: Available evidence comparing diuretic strategies for fluid removal during ICU-level care is limited, clinically heterogeneous, and derived largely from heart failure and post-cardiovascular surgery populations. Bolus loop diuretics were at least comparable to alternate diuretic strategies for patient important outcomes in critically ill adults, but this was based mostly on low or very low certainty evidence. Tolvaptan monotherapy may decrease acute kidney injury, but its effect on subsequent need for RRT and mortality remains uncertain.
参考来源
- Kuriyama A, Polok K, Malhotra N, et al. Diuretic therapy for critically ill patients: a systematic review and network meta-analysis. Ann Intensive Care. 2026. PMID: 42604106. doi:10.1016/j.aicoj.2026.100120
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。